Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend payer with buyback and growth plan to 2030

Hikma Pharmaceuticals PLC has drawn renewed interest from US investors after confirming a 5% dividend increase in 2025 and announcing a $250 million share buyback, alongside a long-term ambition to grow group revenue to $5 billion by 2030, according to a recent commentary by CEO Said Darwazah published via Marketscreener on April 24, 2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

Hikma Pharmaceuticals PLC: core business model

Hikma Pharmaceuticals PLC develops, manufactures, and markets a broad portfolio of generic, branded, and non-branded pharmaceutical products, operating through three main segments: injectables, generics, and branded, according to Morningstar’s company profile as of May 8, 2026.

The injectables segment supplies hospitals with generic injectable medicines, supported by the company’s own manufacturing facilities and a focus on complex, hospital-based products. The generics segment covers oral, nasal, and inhalation products, including the US-focused Hikma Rx business, which generated more than $1 billion in revenue in 2025 and is positioned as the seventh-largest supplier of generic medicines in the United States, according to Darwazah’s Marketscreener commentary dated April 24, 2026.

The branded segment focuses on proprietary products in key therapeutic areas, particularly in the Middle East and North Africa, where Hikma has a long-standing presence and strong distribution networks. This diversified segment mix allows the company to balance volume-driven generic sales with higher-margin branded offerings.

Main revenue and product drivers for Hikma Pharmaceuticals PLC

Geographically, North America is Hikma’s key revenue-generating region, followed by the Middle East and North Africa, the United Kingdom, and other European markets, according to Morningstar’s regional breakdown as of May 8, 2026.

The company’s US oral, nasal, and inhalation generic business, Hikma Rx, has become a core growth engine, with management highlighting its steady transformation toward more complex products, an expanded respiratory and specialty portfolio, and a growing contract-manufacturing offering, which could support higher-margin sales over time.

Hikma’s injectables segment remains a major profit contributor, supplying essential hospital medicines across multiple markets. Recent strategic moves, such as the acquisition of an FDA-approved Abbreviated New Drug Application (ANDA) for trametinib tablets with 180 days of US market exclusivity, underscore the company’s focus on expanding its oncology and specialty generics footprint in the United States, according to a company announcement dated April 2026.

Dividend, buyback and growth plan to 2030

Hikma’s 5% dividend increase in 2025 and the launch of a $250 million share buyback program signal a commitment to returning capital to shareholders while maintaining investment-grade ratings and healthy cash generation, according to recent commentary and market data.

The company’s long-term ambition to grow group revenue to $5 billion by 2030 is underpinned by continued expansion in North America, selective investments in complex generics and injectables, and disciplined portfolio management across its branded and generics businesses.

Why Hikma Pharmaceuticals PLC matters for US investors

For US investors, Hikma offers exposure to a diversified global generics and branded-pharma platform with a strong foothold in the US generic market through Hikma Rx and a growing pipeline of complex and specialty products.

The company’s ADR listing provides access to a business that benefits from secular tailwinds in generic drug demand, hospital injectables, and respiratory therapies, while its London listing and investment-grade profile appeal to income-oriented and long-term investors.

Conclusion

Hikma Pharmaceuticals PLC combines a diversified generics and branded-pharma portfolio with a strong presence in North America and the Middle East, underpinned by a long-term revenue target of $5 billion by 2030 and a track record of dividend growth.

The company’s 5% dividend increase in 2025 and a $250 million share buyback, alongside investment-grade ratings and healthy cash generation, suggest a focus on returning capital to shareholders while funding growth initiatives, according to recent commentary and market data.

For US investors, Hikma offers a blend of income, exposure to the US generic market, and a global footprint, but investors should also consider the competitive pressures in generics, regulatory risks, and the company’s reliance on key markets such as North America and the Middle East.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.